The final phase of DSCSA Drug Supply Chain Security implementation mandates electronic, interoperable product tracing, posing significant enforcement risks for non-compliant pharmaceutical supply chain stakeholders. Immediate action is required to secure verifiable transaction data and avoid severe penalties.
As of June 4, 2026, the U.S. Food and Drug Administration (FDA) has fully transitioned into the enforcement phase for the Drug Supply Chain Security Act (DSCSA), specifically regarding the interoperable electronic tracing of products at the package level. The period of enforcement discretion, which allowed industry stakeholders additional time to implement the complex electronic data exchange requirements (e.g., using EPCIS standards), has definitively concluded. All manufacturers, repackagers, wholesale distributors, and dispensers are now fully accountable for demonstrating compliance with all DSCSA provisions, including the secure, electronic exchange of transaction information (TI), transaction history (TH), and transaction statements (TS) for prescription drug products within the U.S. supply chain.
Non-compliance with the DSCSA, a critical component of the Food, Drug, and Cosmetic Act (FD&C Act), carries substantial legal and financial ramifications. The FDA possesses broad authority to impose civil monetary penalties (CMPs) for violations, which can escalate into hundreds of thousands or even millions of dollars for systemic failures, repeat offenses, or violations impacting public health. For instance, violations related to misbranding or adulteration due to inadequate traceability can incur CMPs up to $1,000,000 per violation for corporations. Beyond direct fines, non-compliant products face immediate detention, refusal of admission, seizure, and potential destruction, leading to significant demurrage, storage, and re-exportation costs. In severe cases of knowing and willful non-compliance, criminal penalties, including imprisonment, may apply. The financial burden of a single shipment hold or product recall due to traceability failures can easily exceed a demurrage threshold of $25,000 USD in direct costs, excluding reputational damage and market disruption.
Exact documentation requirements under the DSCSA are stringent and mandate electronic exchange. Each transaction must include:
Transaction Information (TI): This encompasses the product name, strength, dosage form, National Drug Code (NDC), container size, number of containers, lot number, transaction date, and shipment date. It also requires the business name and address of both the seller and purchaser. Transaction History (TH): A comprehensive statement, in electronic format, of all prior transactions back to the manufacturer of the product. Transaction Statement (TS): A declaration by the seller attesting that they are an authorized trading partner, have received the product from an authorized person, did not knowingly ship suspect or illegitimate product, did not knowingly provide false transaction information, and have systems and processes in place to comply with verification requirements.
These three components (TI, TH, TS) must be exchanged electronically in an interoperable manner, facilitating seamless data flow and verification across the supply chain. The ability to ...